

**Audited Financial Results for the year ended December 31, 2010**

(Rs. In Lacs except EPS and Shares)

Particulars	Standalone		Consolidated	
	For the year ended	For the year ended	For the year ended	For the year ended
	31.12.2010	31.12.2009	31.12.2010	31.12.2009
	<b>Audited</b>	<b>Audited</b>	<b>Audited</b>	<b>Audited</b>
1. (a) Net Sales/Income from Operations	62,559.23	62,473.76	75,233.49	74,352.48
(b) Other Operating Income	109.61	304.84	109.61	304.84
<b>Total Income</b>	<b>62,668.84</b>	<b>62,778.60</b>	<b>75,343.10</b>	<b>74,657.32</b>
2. Expenditure				
a. (Increase) / Decrease in stock in trade and work in	(1,323.08)	(719.58)	(1,588.25)	(622.78)
b. Consumption of raw materials / packing materials	21,313.65	15,905.01	21,313.65	15,905.01
c. Purchase of traded goods	3,156.29	6,487.74	3,883.50	9,084.15
d. Employees cost	4,766.26	3,864.71	5,158.32	4,255.98
e. Depreciation	4,637.80	4,446.00	4,671.59	4,480.69
f. Other expenditure	18,110.73	20,297.01	23,671.16	24,370.63
<b>Total Expenditure</b>	<b>50,661.65</b>	<b>50,280.89</b>	<b>57,109.97</b>	<b>57,473.69</b>
<b>3. Profit from Operations before Other Income, Interest</b>	<b>12,007.19</b>	<b>12,497.71</b>	<b>18,233.13</b>	<b>17,183.63</b>
4. Other Income	1,384.99	1,801.71	1,433.45	1,282.79
<b>5. Profit before Interest and Exceptional Items (3+4)</b>	<b>13,392.19</b>	<b>14,299.42</b>	<b>19,666.58</b>	<b>18,466.42</b>
6. Interest	3,619.40	4,072.86	3,619.58	4,095.79
<b>7. Profit after Interest but before Exceptional Items (5-6)</b>	<b>9,772.79</b>	<b>10,226.56</b>	<b>16,047.00</b>	<b>14,370.62</b>
8. Exceptional items	-	-	-	-
<b>9. Profit (+)/ Loss (-) from Ordinary Activities before tax (7+8)</b>	<b>9,772.79</b>	<b>10,226.56</b>	<b>16,047.00</b>	<b>14,370.62</b>
10. Tax expense	1,870.36	1,320.35	1,902.98	1,334.16
<b>11. Net Profit (+)/ Loss (-) from Ordinary Activities after tax (9-10)</b>	<b>7,902.43</b>	<b>8,906.21</b>	<b>14,144.02</b>	<b>13,036.47</b>
12. Extraordinary Item	-	-	-	-
<b>13. Net Profit(+)/ Loss(-) for the period (11-12)</b>	<b>7,902.43</b>	<b>8,906.21</b>	<b>14,144.02</b>	<b>13,036.47</b>
14. Paid-up equity share capital (Face Value - Rs. 10/- Per Share)	6,381.78	3,412.35	6,381.78	3,412.35
15. Reserve excluding Revaluation Reserves	75,784.05	44,435.69	85,076.19	47,608.27
<b>16. Earnings Per Share (EPS)</b>				
a) Basic EPS	15.27	18.33	27.34	26.94
b) Diluted EPS	15.27	17.40	27.34	25.47
17. Public Shareholding				
- No. of shares	19,783,459	4,867,321	19,783,459	4,867,321
- Percentage of shareholding	31.00%	14.26%	31.00%	14.26%
<b>18. Promoters and Promoter group shareholding</b>				
<b>a) Pledged/Encumbered</b>				
- Number of shares	NIL	NIL	NIL	NIL
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL
- Percentage of shares (as a% of the total share capital of the company)	NIL	NIL	NIL	NIL
<b>b) Non-encumbered</b>				
- Number of Shares	44,034,306	29,256,204	44,034,306	29,256,204
- Percentage of shares (as a% of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%
- Percentage of shares (as a % of the total share capital of the company)	69.00%	85.74%	69.00%	85.74%

**Notes:**

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 24th February 2011.
- 2 In December 2010, the Company has issued and allotted 1,843,003 Equity Shares of Rs.10 each at a premium of Rs.283 per share to Anchor Investors and 10,789,474 Equity Shares of Rs. 10 each at a premium of Rs. 218 per share to investors other than Ancho
- 3 The initial public offer (IPO) proceeds have been utilised as per Objects of Issue as stated in the Prospectus as under :

**A) The Utilisation of Issue Proceeds from IPO is as follows (Rs.in Lacs)**

Particulars of Fund utilisation for	Amount to be utilised as per Prospectus	Amount utilised till 31.12.2010
Setting up of a new plant .....	13,158.50	-
Setting up of new manufacturing line in Clarion IV .....	2,646.80	-
Construction of manufacturing R&D facilities .....	3,840.80	-
Prepayment of Loan .....	4,591.40	4,591.40
General Corporate Purposes .....	3,188.70	-
Issue Expenses .....	2,573.80	1,747.71
<b>Total .....</b>	<b>30,000.00</b>	<b>6,339.11</b>

**B) The unutilised proceeds are invested/held in (Rs.in Lacs)**

Particulars	Amount as on 31.12.2010
Fixed deposits accounts .....	23,071.73
Balance with Escrow Account .....	589.16
<b>Total .....</b>	<b>23,660.89</b>

- 4 The Board of Directors have proposed dividend of Rs.2 per Equity Share of Rs.10 each for the financial year ended December 31, 2010 subject to approval of members at the ensuing Annual General Meeting.
- 5 No investor complaints were received during the period. No complaints were pending either at the beginning or at the end of the period.
- 6 The Company has only one reportable business segment, namely, Drugs & Pharmaceuticals.
- 7 Summarised Audited Balance Sheet

**(Rs. In Lacs)**

Particulars	Standalone		Consolidated	
	As at 31.12.2010	As at 31.12.2009	As at 31.12.2010	As at 31.12.2009
	<b>Audited</b>	<b>Audited</b>	<b>Audited</b>	<b>Audited</b>
<b>Shareholders' Funds:</b>				
(a) Capital	6,381.78	3,412.35	6,381.78	3,412.35
(b) Reserves and Surplus	75,784.07	44,435.71	85,076.19	47,608.27
<b>Loan Funds</b>	36,063.00	31,400.59	36,062.96	31,400.76
<b>Deferred Tax Liability (Net)</b>	5,224.30	5,184.91	5,212.02	5,174.92
<b>TOTAL</b>	<b>123,453.15</b>	<b>84,433.56</b>	<b>132,732.95</b>	<b>87,596.30</b>
<b>Fixed Assets</b>	71,436.36	61,298.85	76,414.07	61,523.27
<b>Investments</b>	1,705.72	1,705.72	1.94	1.94
<b>Goodwill (On Consolidation)</b>	-	-	3.20	3.20
<b>Current Assets, Loans And Advances</b>				
(a) Inventories	13,660.01	12,163.51	15,280.56	13,518.75
(b) Sundry Debtors	25,334.32	24,135.99	24,638.83	26,477.51
(c) Cash and Bank balances	29,064.24	4,353.25	39,560.91	23,694.25
(d) Other current assets	32.65	9.88	32.65	9.89
(e) Loans and Advances	10,826.95	12,004.04	13,521.15	10,354.92
	78,918.17	52,666.67	93,034.10	74,055.32
<b>Less: Current Liabilities and Provisions</b>				
(a) Liabilities	24,953.31	28,298.45	33,103.51	45,168.70
(b) Provisions	3,653.79	2,939.23	3,616.85	2,818.73
<b>TOTAL</b>	<b>123,453.15</b>	<b>84,433.56</b>	<b>132,732.95</b>	<b>87,596.30</b>

- 8 The figures of the previous year have been regrouped or rearranged wherever necessary.

**For Claris Lifesciences Limited**

Sd/-

 Place : Mumbai  
 Date: 24/02/2011

 Arjun S. Handa  
 Managing Director & CEO